drugset / Trial / NCT00813202

An Open-label, One-arm, Study to Evaluate the Hemodynamic Changes and Safety of Nesiritide for Acute Decompensated Heart Failure

NCT00813202

Phase 3 Completed 41 enrolled Xian-Janssen Pharmaceutical Ltd.
RandomizedSingle-groupOpen-labelTreatment

Summary

The present study was an open-label, uncontrolled, and multi-centered phase III clinical trial for evaluation of the efficacy (clinical efficacy and hemodynamics) and safety of nesiritide.

Timeline

Start
2006-10
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Nesiritide Protein / enzyme biologic 0.01 ug/kg Intravenous